The pan-JAK inhibitor tofacitinib (TOF) has emerged as an effective therapeutic option for inducing and maintaining clinical remission in moderate-to-severe UC. Comprehensive in vitro and in vivo assessments of mEXOs@TOF confirmed the enhanced anti-inflammatory treatment on UC, with no detectable adverse effects. Collectively, the mEXOs@TOF nanodelivery system represents a targeted therapeutic strategy for improving UC treatment.

2 days ago

Journal

IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL10 (Interleukin 10)

Gilotrif (afatinib) • tofacitinib

APHP220916: JAK1 inhibitor treatment of inflammatory liver adenomas (2023-505278-13-00)

P1/2, N=50, Active, not recruiting, Assistance Publique Hopitaux De Paris | Recruiting --> Active, not recruiting

2 days ago

Enrollment closed

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis (clinicaltrials.gov)

P2, N=180, Completed, CAGE Bio Inc. | Recruiting --> Completed

5 days ago

Trial completion

tofacitinib

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis (clinicaltrials.gov)

P2, N=3, Completed, CAGE Bio Inc. | Not yet recruiting --> Completed

6 days ago

Trial completion

tofacitinib

Managing Acute Severe Ulcerative Colitis in the Older Patient: A Growing Concern. (PubMed, Drugs Aging)

The conventional sequencing of therapies in acute severe ulcerative colitis-i.e., intravenous steroids followed, in case of refractoriness, by antitumor necrosis factor (TNF) agents, ciclosporin A, or Janus kinase inhibitors such as tofacitinib or upadacitinib-may frequently be contraindicated in older patients or may carry an increased risk of severe adverse events beyond infections. In the absence of specific guidelines, the implementation of and strict adherence to a structured, time-bound decision tree is essential in order to avoid unnecessarily prolonged treatment with systemic steroids in frail patients, which may lead to deleterious outcomes, particularly in those requiring surgery. Recent reports on adjunctive measures, such as hyperbaric oxygen therapy or total enteral nutrition, may also be considered given their encouraging safety profile.

7 days ago

Review • Journal

TNFA (Tumor Necrosis Factor-Alpha)

tofacitinib

P30CA015704: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (clinicaltrials.gov)

P2, N=61, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed

8 days ago

Trial completion

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan

RHODOLITE: Registry Platform Myelofibrosis and Anemia (clinicaltrials.gov)

P=N/A, N=200, Recruiting, iOMEDICO AG | Not yet recruiting --> Recruiting

8 days ago

Enrollment open • HEOR

ChronIA001: Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients from a patient's, clinical as well as a translational point of view. (2024-517865-17-01)

P4, N=84, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting

9 days ago

Enrollment open

Xeljanz XR (tofacitinib XR)

PRIMERA001: Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account. (2024-511530-12-01)

P4, N=300, Active, not recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Active, not recruiting